Crestline Management LP Acquires New Position in Envista Holdings Co. (NYSE:NVST)

Crestline Management LP purchased a new stake in shares of Envista Holdings Co. (NYSE:NVST) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 84,794 shares of the company’s stock, valued at approximately $1,636,000.

Several other institutional investors have also modified their holdings of the company. GAMMA Investing LLC grew its stake in Envista by 30.5% in the 4th quarter. GAMMA Investing LLC now owns 2,304 shares of the company’s stock valued at $44,000 after acquiring an additional 538 shares during the last quarter. First Hawaiian Bank grew its position in shares of Envista by 19.9% in the fourth quarter. First Hawaiian Bank now owns 32,285 shares of the company’s stock valued at $623,000 after purchasing an additional 5,363 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of Envista during the 4th quarter worth approximately $53,000. Profit Investment Management LLC raised its position in shares of Envista by 6.0% during the 4th quarter. Profit Investment Management LLC now owns 127,597 shares of the company’s stock worth $2,461,000 after purchasing an additional 7,226 shares during the last quarter. Finally, Hedges Asset Management LLC lifted its stake in Envista by 13.9% in the 4th quarter. Hedges Asset Management LLC now owns 53,300 shares of the company’s stock valued at $1,028,000 after buying an additional 6,500 shares in the last quarter.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Robert W. Baird set a $21.00 price target on Envista in a report on Friday, May 2nd. Piper Sandler cut their target price on shares of Envista from $18.00 to $17.00 and set a “neutral” rating for the company in a research note on Wednesday, April 30th. Needham & Company LLC reaffirmed a “hold” rating on shares of Envista in a research note on Thursday, March 6th. UBS Group lowered their price target on shares of Envista from $21.00 to $18.00 and set a “neutral” rating for the company in a report on Monday. Finally, Morgan Stanley set a $16.00 price objective on shares of Envista in a research note on Tuesday, April 15th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, Envista has an average rating of “Hold” and an average target price of $20.08.

Envista Trading Up 5.5 %

NVST stock opened at $17.77 on Friday. Envista Holdings Co. has a 52 week low of $14.22 and a 52 week high of $23.00. The company has a market cap of $3.01 billion, a price-to-earnings ratio of -2.74, a PEG ratio of 1.27 and a beta of 0.97. The company has a quick ratio of 1.76, a current ratio of 2.04 and a debt-to-equity ratio of 0.44. The business has a fifty day simple moving average of $16.50 and a 200-day simple moving average of $19.00.

Envista (NYSE:NVST) last announced its quarterly earnings results on Thursday, May 1st. The company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.20 by $0.04. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. The company had revenue of $616.90 million during the quarter, compared to analyst estimates of $608.17 million. During the same period in the prior year, the firm posted $0.26 earnings per share. The firm’s revenue was down 1.1% on a year-over-year basis. On average, equities research analysts expect that Envista Holdings Co. will post 1 EPS for the current year.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.